{"id":1719,"date":"2014-07-30T18:46:49","date_gmt":"2014-07-30T16:46:49","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=1719"},"modified":"2014-08-13T20:09:21","modified_gmt":"2014-08-13T18:09:21","slug":"amgen-annuncia-2-900-esuberi-titolo-in-progresso-del-3-in-pre-market-al-nasdaq","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/amgen-annuncia-2-900-esuberi-titolo-in-progresso-del-3-in-pre-market-al-nasdaq\/","title":{"rendered":"Amgen announces 2,900 redundancies. Stock in progress of 3% in pre-market on the Nasdaq"},"content":{"rendered":"

Amgen<\/span><\/a><\/span> announced a plan to reduce its workforce by 12-15% (up to a maximum of 2,900 redundancies) as part of a refocusing of resources on the development of new drugs (last year the US group acquired Onyx Pharmaceuticals<\/span><\/a><\/span> for $10.4 billion to buy Kyprolis, a drug for the treatment of multiple myeloma). The redundancy announcement came alongside second-quarter results marked by 23% earnings progressing to $1.55 billion, or $2.01 per share. Adjusted EPS was $2.37, while 11% revenues grew to $5.18 billion. Thomson Reuters analysts estimated EPS on average at $2.07 on $4.9 billion in revenue. The Amgen title<\/span><\/a><\/span> which gained 0.54% on Wall Street on Tuesday, trading was up more than 3% in pre-market on the Nasdaq.<\/p>\n

07\/30\/2014 Online trends<\/span><\/a><\/b><\/span><\/p>\n

Amgen Adjusted Quarterly Earnings Above Expectations<\/span><\/a><\/span><\/p>\n

Amgen: agreement for the acquisition of Biovex Group for 1 billion dollars<\/span><\/a><\/span><\/p>\n

\u00a0Financial Times<\/span><\/a><\/p>\n

\"\"Robert A. Bradway<\/span><\/a><\/b><\/span> he is Chairman, Chief Executive Officer, Chairman of the Executive Committee, etc. Of Amgen Inc.<\/span><\/a>. During 2013 he received a total fee of $13,649,807 equal to \u20ac 10.201.497<\/b> ($ 1.34 gearbox)<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

TO<\/p>","protected":false},"excerpt":{"rendered":"

Amgen ha annunciato un piano di riduzione della sua forza lavoro del 12-15% (fino a un massimo di 2.900 esuberi) all’interno di una rifocalizzazione delle risorse sullo sviluppo di nuovi farmaci (lo scorso anno il gruppo Usa ha rilevato Onyx Pharmaceuticals per 10,4 miliardi di dollari con l’obiettivo di conquistare il Kyprolis, farmaco per il …<\/p>","protected":false},"author":4,"featured_media":1727,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,16],"tags":[47,51,27],"class_list":["post-1719","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","category-primo-piano","tag-big-pharma","tag-compenso-top-manager","tag-licenziati"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/1719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=1719"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/1719\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/1727"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=1719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=1719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=1719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}